Zacks Investment Research·1d ago
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic ArthritisABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.
AbbVie's accelerating revenue growth, driven by Skyrizi and Rinvoq, has expanded gross margins to 74.7% in 2026Q2, but the company's balance sheet remains strained with negative equity of -$5.9B and total debt of $70.8B. While free cash flow generation is robu...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 10.2% YoY in 2026Q2, with gross margin expanding to 74.7% and operating margin reaching 37.9%, reflecting a favorable mix shift toward higher-margin newer drugs.
AbbVie is experiencing strong growth in immunology with drugs like Skyrizi and Rinvoq, which are expected to drive continued earnings growth.
Analysts hold a consensus rating of 'Buy' for AbbVie, indicating confidence in the stock's future performance.
Management has raised full-year guidance, reflecting confidence in AbbVie's future earnings potential.
AbbVie has a trailing P/E ratio that is significantly higher than the industry average, raising concerns about overvaluation.
There are worries about margin compression and a recent large one-off loss that negatively impacted net income.
AbbVie relies heavily on a concentrated group of therapies, making it vulnerable to biosimilar competition, especially as Humira sales decline.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 31, 2026 | $3.65+1.1% vs $3.61 | $17.0B+1.1% vs $16.8B |
Q2 2026 Apr 29, 2026 | $2.65+2.3% vs $2.59 | $15.0B+1.9% vs $14.7B |
Q1 2026 Feb 4, 2026 | $2.71+2.3% vs $2.65 | $16.6B+1.2% vs $16.4B |
Q4 2025 Oct 31, 2025 | $1.86+5.1% vs $1.77 | $15.8B+1.2% vs $15.6B |
ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.
AA Signature: SKIN360 marks the first in a series of assessment protocols addressing patients' evolving aesthetic goals. The program includes provider education and resources to support 96% of patients who are interested in a comprehensive aesthetic consultation.
Dividend payments offer you security in difficult markets -- and extra growth in better times. These pharma companies offer dividend yields that beat the dividend yield of the S&P 500.
With the third quarter closing out, income investors have a narrow window to lock in three cash-generative blue chips before Q3 earnings reset expectations. The shared hook: recession-resilient franchises, multi-decade dividend histories, and reaffirmed or raised 2026 guidance.
Benchmark ABBV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AbbVie Inc. (ABBV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $265.32 | $468.77B | 111.95 | 8.57% | 6.91% | 6214.71% | 2.48% | |
| $269.19 | $648B | 24.41 | 6.05% | 21.58% | 25.75% | — | |
| $150.92 | $372.73B | 20.73 | 1.18% | 4.78% | 6.59% | — | |
| $27.93 | $159.19B | 20.54 | -1.65% | 6.81% | 4.87% | — | |
| $62.25 | $127.12B | 18.04 | -0.22% | 18.87% | 46.69% | — | |
| $1170.48 | $1.1T | 51.00 | 44.7% | 33.53% | 92.53% | — |
AbbVie Inc. (ABBV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AbbVie Inc. (ABBV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 18, 2026·SEC
Aug 5, 2026·SEC
Jul 31, 2026·SEC
Get notified when ABBV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AbbVie Inc. (ABBV) stock FAQ — growth, dividends, profitability & financials explained
AbbVie Inc. (ABBV) reported $64.39B in revenue for fiscal year 2025. This represents a 312% increase from $15.64B in 2010.
AbbVie Inc. (ABBV) grew revenue by 8.6% over the past year. This is steady growth.
Yes, AbbVie Inc. (ABBV) is profitable, generating $6.31B in net income for fiscal year 2025 (6.9% net margin).
Yes, AbbVie Inc. (ABBV) pays a dividend with a yield of 2.48%. This makes it attractive for income-focused investors.
AbbVie Inc. (ABBV) has a return on equity (ROE) of 6214.7%. This is excellent, indicating efficient use of shareholder capital.
AbbVie Inc. (ABBV) generated $19.68B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
